Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Forman

Showing results (881-890 of 1,052) with videos related to

Pageof 106
Sort By:
Bone Marrow Transplantation|November 21, 2021
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimensJanny M Yao, Dongyun Yang, Mary C Clark, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
American Journal of Hematology|May 27, 2024
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemiaTamer Othman, Shanpeng Li, Jianying Zhang, et al.
Blood|June 14, 2022
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Bone Marrow Transplantation|December 15, 2010
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemiaA S Stein, M R O'Donnell, T W Synold, et al.
Blood|August 1, 2022
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Leukemia & Lymphoma|April 10, 2020
Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 studyMichael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, et al.
British Journal of Cancer|June 13, 2001
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcomeG Somlo, J H Doroshow, T Synold, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 27, 2020
Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantationSaro H Armenian, Aleksi Iukuridze, Jennifer Berano Teh, et al.
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Pageof 106

Showing results (881-890 of 1,052) with videos related to

Sort By:
Pageof 106
Bone Marrow Transplantation|November 21, 2021
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimensJanny M Yao, Dongyun Yang, Mary C Clark, et al.
American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.
American Journal of Hematology|May 27, 2024
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemiaTamer Othman, Shanpeng Li, Jianying Zhang, et al.
Blood|June 14, 2022
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Bone Marrow Transplantation|December 15, 2010
Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemiaA S Stein, M R O'Donnell, T W Synold, et al.
Blood|August 1, 2022
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Leukemia & Lymphoma|April 10, 2020
Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 studyMichael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, et al.
British Journal of Cancer|June 13, 2001
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcomeG Somlo, J H Doroshow, T Synold, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 27, 2020
Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantationSaro H Armenian, Aleksi Iukuridze, Jennifer Berano Teh, et al.
Hemasphere|May 2, 2025
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphomaMatthew Mei, Joycelynne Palmer, Hun Ju Lee, et al.
Pageof 106